RetroSense Therapeutics CEO Sean Ainsworth explains how the company’s optogenetic gene therapeutic can impart light sensitivity to cells in the retina, re-sensitizing it to light. The company is pursuing treatments for Dry AMD and retinitis pigementosa.
RetroSense Therapeutics is developing optogenetic gene therapeutic approaches to vision restoration. Optogenetics imparts light sensitivity to cells in the retina, re-sensitizing it to light. We recently initiated a Phase I/II clinical study in retinitis pigmentosa (orphan designation granted). There are currently no approved drugs for retinitis pigmentosa or dry AMD.